<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01959841</url>
  </required_header>
  <id_info>
    <org_study_id>M522101-J01</org_study_id>
    <nct_id>NCT01959841</nct_id>
  </id_info>
  <brief_title>Phase III Study of ASP2151 in Herpes Zoster Patients</brief_title>
  <official_title>Phase III Study of ASP2151 in Herpes Zoster Patients― A Double-blind, Valaciclovir-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maruho Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maruho Co., Ltd.</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of ASP2151 (200 mg and 400 mg) in comparison with
      valaciclovir (VACV) 3000 mg in patients with herpes zoster.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, randomized, parallel-group study will be conducted to evaluate the efficacy
      and safety of ASP2151 (200 mg and 400 mg) in comparison with valaciclovir (VACV) 3000 mg in
      patients with herpes zoster. The efficacy will be evaluated for the primary endpoint defined
      as, &quot;the proportion of subjects achieving cessation of new lesion formation by Day 4 of study
      treatment&quot; to demonstrate the non-inferiority of ASP2151 to VACV. The safety will be
      evaluated based on adverse events, laboratory tests, vital signs, and ECGs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">July 10, 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Participants Achieving Cessation of New Lesion Formation by Day 4 of Study Treatment</measure>
    <time_frame>4days</time_frame>
    <description>The investigator assessed the Number of rashes (erythemas/papulae and vesicles/pustules). The &quot;new lesion formation&quot; was defined as the state in which the number of rashes is increasing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Cessation of New Lesion Formation</measure>
    <time_frame>29days</time_frame>
    <description>The investigator assessed the Number of rashes (erythemas/papulae and vesicles/pustules). The &quot;new lesion formation&quot; was defined as the state in which the number of rashes is increasing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Complete Crusting</measure>
    <time_frame>29days</time_frame>
    <description>We defined the following state as &quot;Complete crusting&quot;.
A condition where all lesions of erythemas/papulae, vesicles/pustules, and erosions/ulcers have disappeared, and all rashes are crusted (epithelialization of the base of crusts is not required).
In subjects with no formation of vesicles or pustules, a condition where all lesions of erythemas/papulae have disappeared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Healing</measure>
    <time_frame>29days</time_frame>
    <description>We defined the following state as &quot;Healing&quot;.
A condition where all lesions of erythemas/papulae, vesicles/pustules, and erosions/ulcers have disappeared, and complete disappearance of crusts or complete epithelialization of the base of crusts are considered to have been achieved.
In subjects with no formation of vesicles or pustules, a condition where all lesions of erythemas/papulae have disappeared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Pain Resolution</measure>
    <time_frame>29days</time_frame>
    <description>Investigators assessed the pain using NRS. The date of pain resolution is defined as the first day when all NRS scores are rated as 2 or less, and such scores are continuously observed until Day 92 or discontinuation visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Virus Disappearance</measure>
    <time_frame>29days</time_frame>
    <description>Virus desiappearance was defined as the participants who who reached virus-negative status according to the virus isolation and culture assay or whose samples were not available because of complete crusting or healing</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">751</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>ASP2151(200 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP2151(400mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>valaciclovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg three times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP2151</intervention_name>
    <description>200 mg once daily or 400 mg once daily</description>
    <arm_group_label>ASP2151(200 mg)</arm_group_label>
    <arm_group_label>ASP2151(400mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valaciclovir</intervention_name>
    <description>1000 mg three times daily</description>
    <arm_group_label>valaciclovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        (1) Patients who have a rash associated with herpes zoster, and who can start receiving the
        study drug within 72 hours after onset of the rash

        Exclusion Criteria:

          1. Patients who are not expected to have an adequate response to oral antiviral
             medication

          2. An extreme decline in immune function

          3. Presence of serious complications

          4. Patients found to meet any of the following conditions based on laboratory tests
             performed within 14 days before informed consent:

               -  AST or ALT ≥ 2.5 x upper limit of normal

               -  Platelet count &lt; lower limit of normal

               -  Serum creatinine ≥ 1.5 mg/dL

               -  Creatinine clearance &lt; 50 mL/min

          5. Current or previous history of malignant tumor within 5 years before informed consent

          6. Diagnosis of autoimmune disease

          7. Evidence of bone marrow suppression
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maruho Co.,Ltd. Kyoto R&amp;D Center</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Development Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nakano-Ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 26, 2013</study_first_submitted>
  <study_first_submitted_qc>October 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <results_first_submitted>March 22, 2018</results_first_submitted>
  <results_first_submitted_qc>March 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 18, 2018</results_first_posted>
  <last_update_submitted>October 31, 2018</last_update_submitted>
  <last_update_submitted_qc>October 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 106 sites in Japan from September 2013 to Jully 2015</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ASP2151(200 mg)</title>
          <description>once daily
ASP2151: 200 mg once daily or 400 mg once daily</description>
        </group>
        <group group_id="P2">
          <title>ASP2151(400mg)</title>
          <description>once daily
ASP2151: 200 mg once daily or 400 mg once daily</description>
        </group>
        <group group_id="P3">
          <title>Valaciclovir</title>
          <description>1000 mg three times daily
valaciclovir: 1000 mg three times daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="252"/>
                <participants group_id="P2" count="250"/>
                <participants group_id="P3" count="249"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set Included</title>
              <participants_list>
                <participants group_id="P1" count="247"/>
                <participants group_id="P2" count="243"/>
                <participants group_id="P3" count="245"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set Excluded</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Reason FAS Excluding 1</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Reason FAS Excluding 2</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Reason FAS Excluding 3</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="193"/>
                <participants group_id="P3" count="206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical laboratory value</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Platelet count below on day1 or 4</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The full analysis set(FAS).The FAS was defined as patients who were diagnosed with herpes zoster at the time of case registration, who subsequently received the study drugs, and had any efficacy variable measured.</population>
      <group_list>
        <group group_id="B1">
          <title>ASP2151(200 mg)</title>
          <description>once daily
ASP2151: 200 mg once daily or 400 mg once daily</description>
        </group>
        <group group_id="B2">
          <title>ASP2151(400mg)</title>
          <description>once daily
ASP2151: 200 mg once daily or 400 mg once daily</description>
        </group>
        <group group_id="B3">
          <title>Valaciclovir</title>
          <description>1000 mg three times daily
valaciclovir: 1000 mg three times daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="247"/>
            <count group_id="B2" value="243"/>
            <count group_id="B3" value="245"/>
            <count group_id="B4" value="735"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="178"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="178"/>
                    <measurement group_id="B4" value="530"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.0" spread="16.3"/>
                    <measurement group_id="B2" value="53.0" spread="16.2"/>
                    <measurement group_id="B3" value="52.2" spread="15.8"/>
                    <measurement group_id="B4" value="52.39" spread="16.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="146"/>
                    <measurement group_id="B4" value="424"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                    <measurement group_id="B2" value="243"/>
                    <measurement group_id="B3" value="245"/>
                    <measurement group_id="B4" value="735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                    <measurement group_id="B2" value="243"/>
                    <measurement group_id="B3" value="245"/>
                    <measurement group_id="B4" value="735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                    <measurement group_id="B2" value="243"/>
                    <measurement group_id="B3" value="245"/>
                    <measurement group_id="B4" value="735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from onset of rash to the first dose</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>within 24 hours</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="154"/>
                  </measurement_list>
                </category>
                <category>
                  <title>over 24 hours, within 48 hours</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="281"/>
                  </measurement_list>
                </category>
                <category>
                  <title>over 48 hours, within 72 hours</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Achieving Cessation of New Lesion Formation by Day 4 of Study Treatment</title>
        <description>The investigator assessed the Number of rashes (erythemas/papulae and vesicles/pustules). The &quot;new lesion formation&quot; was defined as the state in which the number of rashes is increasing.</description>
        <time_frame>4days</time_frame>
        <population>The full analysis set(FAS).The FAS was defined as patients who were diagnosed with herpes zoster at the time of case registration, who subsequently received the study drugs, and had any efficacy variable measured.</population>
        <group_list>
          <group group_id="O1">
            <title>ASP2151(200 mg)</title>
            <description>once daily
ASP2151: 200 mg once daily or 400 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>ASP2151(400mg)</title>
            <description>once daily
ASP2151: 200 mg once daily or 400 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Valaciclovir</title>
            <description>1000 mg three times daily
valaciclovir: 1000 mg three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Achieving Cessation of New Lesion Formation by Day 4 of Study Treatment</title>
          <description>The investigator assessed the Number of rashes (erythemas/papulae and vesicles/pustules). The &quot;new lesion formation&quot; was defined as the state in which the number of rashes is increasing.</description>
          <population>The full analysis set(FAS).The FAS was defined as patients who were diagnosed with herpes zoster at the time of case registration, who subsequently received the study drugs, and had any efficacy variable measured.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6"/>
                    <measurement group_id="O2" value="81.1"/>
                    <measurement group_id="O3" value="75.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The non-inferiority of each ASP2151 dose level versus valaciclovir was assessed stepwise using a closed testing procedure.First step analysis was performed in the ASP2151(400mg) once daily.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Wherein the non-inferiority margin was set at 10%. If the one-sided P-value was less than 0.025 between the ASP2151(400mg) once daily and the valaciclovir 1000 mg three times daily, non-inferiority of ASP2151 to valaciclovir was assumed.</non_inferiority_desc>
            <p_value>0.00000241</p_value>
            <method>Modified Farrington–Manning test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The analysis was performed in the ASP2151(200 mg) once daily only when non-inferiority of the ASP2151(400 mg) 0nce daily to valaciclovir 1000 mg three times daily was assumed.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Wherein the non-inferiority margin was set at 10%. If the one-sided P-value was less than 0.025 between the ASP2151(200mg) once daily and the valaciclovir 1000 mg three times daily, non-inferiority of ASP2151 to valaciclovir was assumed.</non_inferiority_desc>
            <p_value>0.0688</p_value>
            <method>Modified Farrington–Manning test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cessation of New Lesion Formation</title>
        <description>The investigator assessed the Number of rashes (erythemas/papulae and vesicles/pustules). The &quot;new lesion formation&quot; was defined as the state in which the number of rashes is increasing.</description>
        <time_frame>29days</time_frame>
        <population>The full analysis set(FAS).The FAS was defined as patients who were diagnosed with herpes zoster at the time of case registration, who subsequently received the study drugs, and had any efficacy variable measured.</population>
        <group_list>
          <group group_id="O1">
            <title>ASP2151(200 mg)</title>
            <description>once daily
ASP2151: 200 mg once daily or 400 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>ASP2151(400mg)</title>
            <description>once daily
ASP2151: 200 mg once daily or 400 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Valaciclovir</title>
            <description>1000 mg three times daily
valaciclovir: 1000 mg three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cessation of New Lesion Formation</title>
          <description>The investigator assessed the Number of rashes (erythemas/papulae and vesicles/pustules). The &quot;new lesion formation&quot; was defined as the state in which the number of rashes is increasing.</description>
          <population>The full analysis set(FAS).The FAS was defined as patients who were diagnosed with herpes zoster at the time of case registration, who subsequently received the study drugs, and had any efficacy variable measured.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="3" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Complete Crusting</title>
        <description>We defined the following state as &quot;Complete crusting&quot;.
A condition where all lesions of erythemas/papulae, vesicles/pustules, and erosions/ulcers have disappeared, and all rashes are crusted (epithelialization of the base of crusts is not required).
In subjects with no formation of vesicles or pustules, a condition where all lesions of erythemas/papulae have disappeared.</description>
        <time_frame>29days</time_frame>
        <population>The full analysis set(FAS).The FAS was defined as patients who were diagnosed with herpes zoster at the time of case registration, who subsequently received the study drugs, and had any efficacy variable measured.</population>
        <group_list>
          <group group_id="O1">
            <title>ASP2151(200 mg)</title>
            <description>once daily
ASP2151: 200 mg once daily or 400 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>ASP2151(400mg)</title>
            <description>once daily
ASP2151: 200 mg once daily or 400 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Valaciclovir</title>
            <description>1000 mg three times daily
valaciclovir: 1000 mg three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Complete Crusting</title>
          <description>We defined the following state as &quot;Complete crusting&quot;.
A condition where all lesions of erythemas/papulae, vesicles/pustules, and erosions/ulcers have disappeared, and all rashes are crusted (epithelialization of the base of crusts is not required).
In subjects with no formation of vesicles or pustules, a condition where all lesions of erythemas/papulae have disappeared.</description>
          <population>The full analysis set(FAS).The FAS was defined as patients who were diagnosed with herpes zoster at the time of case registration, who subsequently received the study drugs, and had any efficacy variable measured.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="6" upper_limit="11"/>
                    <measurement group_id="O2" value="9" lower_limit="7" upper_limit="11"/>
                    <measurement group_id="O3" value="8" lower_limit="7" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Healing</title>
        <description>We defined the following state as &quot;Healing&quot;.
A condition where all lesions of erythemas/papulae, vesicles/pustules, and erosions/ulcers have disappeared, and complete disappearance of crusts or complete epithelialization of the base of crusts are considered to have been achieved.
In subjects with no formation of vesicles or pustules, a condition where all lesions of erythemas/papulae have disappeared</description>
        <time_frame>29days</time_frame>
        <population>The full analysis set(FAS).The FAS was defined as patients who were diagnosed with herpes zoster at the time of case registration, who subsequently received the study drugs, and had any efficacy variable measured.</population>
        <group_list>
          <group group_id="O1">
            <title>ASP2151(200 mg)</title>
            <description>once daily
ASP2151: 200 mg once daily or 400 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>ASP2151(400mg)</title>
            <description>once daily
ASP2151: 200 mg once daily or 400 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Valaciclovir</title>
            <description>1000 mg three times daily
valaciclovir: 1000 mg three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Healing</title>
          <description>We defined the following state as &quot;Healing&quot;.
A condition where all lesions of erythemas/papulae, vesicles/pustules, and erosions/ulcers have disappeared, and complete disappearance of crusts or complete epithelialization of the base of crusts are considered to have been achieved.
In subjects with no formation of vesicles or pustules, a condition where all lesions of erythemas/papulae have disappeared</description>
          <population>The full analysis set(FAS).The FAS was defined as patients who were diagnosed with herpes zoster at the time of case registration, who subsequently received the study drugs, and had any efficacy variable measured.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="8" upper_limit="15"/>
                    <measurement group_id="O2" value="11" lower_limit="8" upper_limit="15"/>
                    <measurement group_id="O3" value="11" lower_limit="8" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Pain Resolution</title>
        <description>Investigators assessed the pain using NRS. The date of pain resolution is defined as the first day when all NRS scores are rated as 2 or less, and such scores are continuously observed until Day 92 or discontinuation visit.</description>
        <time_frame>29days</time_frame>
        <population>The full analysis set(FAS).The FAS was defined as patients who were diagnosed with herpes zoster at the time of case registration, who subsequently received the study drugs, and had any efficacy variable measured.</population>
        <group_list>
          <group group_id="O1">
            <title>ASP2151(200 mg)</title>
            <description>once daily
ASP2151: 200 mg once daily or 400 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>ASP2151(400mg)</title>
            <description>once daily
ASP2151: 200 mg once daily or 400 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Valaciclovir</title>
            <description>1000 mg three times daily
valaciclovir: 1000 mg three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Pain Resolution</title>
          <description>Investigators assessed the pain using NRS. The date of pain resolution is defined as the first day when all NRS scores are rated as 2 or less, and such scores are continuously observed until Day 92 or discontinuation visit.</description>
          <population>The full analysis set(FAS).The FAS was defined as patients who were diagnosed with herpes zoster at the time of case registration, who subsequently received the study drugs, and had any efficacy variable measured.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="5" upper_limit="19"/>
                    <measurement group_id="O2" value="10" lower_limit="5" upper_limit="19"/>
                    <measurement group_id="O3" value="10" lower_limit="5" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Virus Disappearance</title>
        <description>Virus desiappearance was defined as the participants who who reached virus-negative status according to the virus isolation and culture assay or whose samples were not available because of complete crusting or healing</description>
        <time_frame>29days</time_frame>
        <population>The full analysis set(FAS).The FAS was defined as patients who were diagnosed with herpes zoster at the time of case registration, who subsequently received the study drugs, and had any efficacy variable measured.</population>
        <group_list>
          <group group_id="O1">
            <title>ASP2151(200 mg)</title>
            <description>once daily
ASP2151: 200 mg once daily or 400 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>ASP2151(400mg)</title>
            <description>once daily
ASP2151: 200 mg once daily or 400 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Valaciclovir</title>
            <description>1000 mg three times daily
valaciclovir: 1000 mg three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Virus Disappearance</title>
          <description>Virus desiappearance was defined as the participants who who reached virus-negative status according to the virus isolation and culture assay or whose samples were not available because of complete crusting or healing</description>
          <population>The full analysis set(FAS).The FAS was defined as patients who were diagnosed with herpes zoster at the time of case registration, who subsequently received the study drugs, and had any efficacy variable measured.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O2" value="5" lower_limit="4" upper_limit="10"/>
                    <measurement group_id="O3" value="4" lower_limit="3" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>92 days</time_frame>
      <desc>Participant who has not received any study drug after randomization excluded from the Number participants at Risk</desc>
      <group_list>
        <group group_id="E1">
          <title>ASP2151(200 mg)</title>
          <description>once daily
ASP2151: 200 mg once daily or 400 mg once daily</description>
        </group>
        <group group_id="E2">
          <title>ASP2151(400mg)</title>
          <description>once daily
ASP2151: 200 mg once daily or 400 mg once daily</description>
        </group>
        <group group_id="E3">
          <title>Valaciclovir</title>
          <description>1000 mg three times daily
valaciclovir: 1000 mg three times daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA/J Ver. 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Embolic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA/J Ver. 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Beta-N-acetyl-D-glucosaminidase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Fibrin degradation products increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Alpha 1 microglobulin increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>linical Development Dept.</name_or_title>
      <organization>Maruho Co.,Ltd. Kyoto R&amp;D Center</organization>
      <phone>+81-75-325-3255</phone>
      <email>ctinfo@mii.maruho.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

